Bumetanide

Bumetanide

SCHEMBL27525

CCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC12A1

The experimentally established mechanism targets of Bumetanide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 1.00
USP2 O75604 2/20 1.00
ALDH1A1 P00352 2/20 1.00
LMNA P02545 2/20 1.00
HPGD P15428 2/20 1.00
HIF1A Q16665 2/20 1.00
HSD17B10 Q99714 2/20 1.00
CA2 P00918 1/20 1.00
TSHR P16473 1/20 1.00
BLM P54132 1/20 1.00
SLC12A2 P55011 1/20 1.00
NPSR1 Q6W5P4 1/20 1.00
AQP1 P29972 1/20 0.73
PTGS2 P35354 16/20 0.70
SLC6A4 P31645 1/20 0.52
CISD1 Q9NZ45 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bumetanide SCHEMBL4425232 1.00 KDM4E (1.00) KDM4EUSP2ALDH1A1LMNAHPGD
Bumetanide SCHEMBL29388271 1.00 KDM4E (1.00) KDM4EUSP2ALDH1A1LMNAHPGD
Bumetanide SCHEMBL6239781 0.99 KDM4E (0.98) KDM4EUSP2ALDH1A1LMNAHPGD
Bumetanide SCHEMBL251062 0.99 KDM4E (0.98) KDM4EUSP2ALDH1A1LMNAHPGD
Bumetanide SCHEMBL2255359 0.99 KDM4E (0.98) KDM4EUSP2ALDH1A1LMNAHPGD
Bumetanide SCHEMBL23455698 0.99 KDM4E (0.98) KDM4EUSP2ALDH1A1LMNAHPGD
Bumetanide SCHEMBL28661289 0.99 KDM4E (0.98) KDM4EUSP2ALDH1A1LMNAHPGD
Bumetanide SCHEMBL28549675 0.98 KDM4E (0.96) KDM4EUSP2ALDH1A1LMNAHPGD
Bumetanide SCHEMBL250621 0.98 KDM4E (0.96) KDM4EUSP2ALDH1A1LMNAHPGD
SCHEMBL11840406 0.97 KDM4E (0.94) KDM4EUSP2ALDH1A1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 23774 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026106917-A1 EDIBLE TRANSMUCOSAL DRUG DELIVERY METHOD USING AN INTERMEDIATE CAPSULE AS A TEMPORARY VESSEL BioPhysics Pharma, Inc. (US) 2026-05-21 WO claimed
WO-2026090360-A1 FUSED PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, HEARING LOSS, AND MENIERE'S DISEASE OVID THERAPEUTICS INC. (US) 2026-04-30 WO claimed
EP-3934654-B1 ISTAROXIME OR ITS METABOLITE PST-3093 FOR USE AS INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE (AHF) WINDTREE THERAPEUTICS INC (US) 2026-04-29 EP claimed
EP-4731194-A1 MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT CSP Technologies, Inc. (US) 2026-04-29 EP claimed
US-20260108529-A1 FUSED AMINO PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, ACUTE SENSORINEURAL HEARING LOSS, AGE-RELATED HEARING LOSS, AND MENIERE'S DISEASE OVID THERAPEUTICS INC (US) 2026-04-23 US claimed
US-12605345-B2 Transdermal drug delivery system BioPhysics Pharma, Inc. (US) 2026-04-21 US claimed
EP-4722714-A1 SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) Korea Institute of Science and Technology (KR) 2026-04-08 EP claimed
EP-4719435-A2 COMPOSITIONS TO TREAT OBESITY BY TARGETING KCC2 AND NKCC1 The Jackson Laboratory (US) 2026-04-08 EP claimed
EP-4710928-A2 METHODS OF TREATING IGA NEPHROPATHY WITH ATRASENTAN Chinook Therapeutics, Inc. (US) 2026-03-18 EP claimed
WO-2026043819-A1 FORMULATIONS AND METHODS FOR CONVENIENT AND RAPID DIURESIS FOR THE TREATMENT OF EDEMA STRATEGIC DRUG SOLUTIONS, INC. (US) 2026-02-26 WO claimed
EP-0049842-A2 Substituted enantholactam derivatives, a process for the preparation and a pharmaceutical composition useful in the treatment of hypertension comprising the same, and intermediates MERCK & CO. INC. (US) 1982-04-21 EP claimed
EP-0049505-A2 Substituted caprolactam derivatives, a process for preparing and a pharmaceutical composition containing the same, and intermediates MERCK & CO. INC. (US) 1982-04-14 EP claimed
EP-0046291-A2 Substituted caprolactam derivatives as antihypertensives, process for preparing them, pharmaceutical composition containing them, and intermediates MERCK & CO. INC. (US) 1982-02-24 EP claimed
US-4311697-A HYPOTENSIVE AGENTS E. R. SQUIBB & SONS, INC. (US) 1982-01-19 US claimed
US-4285947-A DIURETICS, HYPOTENSIVES INTERX RESEARCH CORPORATION (US) 1981-08-25 US claimed
EP-0032725-A1 Novel aldehyde adducts of triamterene and a pharmaceutical composition containing the same MERCK & CO. INC. (US) 1981-07-29 EP claimed
US-4261985-A REDUCED EXCRETION OF POTASSIUM IONS BY INCLUSION OF ALDOSTERONE ANTAGONIST CIBA-GEIGY CORPORATION (US) 1981-04-14 US claimed
US-4217347-A MERCAPTOALKYL ALKANOYLPROLINES AND A DIURETIC E. R. SQUIBB & SONS, INC. (US) 1980-08-12 US claimed
EP-0011818-A1 Medicaments and pharmaceutical compositions based on aldosterone antagonists and diuretics and process for their manufacture CIBA-GEIGY AG (CH) 1980-06-11 EP claimed
US-4110445-A METHOD FOR ANTAGONIZING ALDOSTERONIC ACTION AND INDUCING DIURESIS BY ADMINISTERING A TETRASUBSTITUTED IMIDAZOLIDINE AMERICAN CYANAMID COMPANY (US) 1978-08-29 US claimed